Cargando…
Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer’s disease PET studies
In Alzheimer’s Disease (AD) dual-tracer positron emission tomography (PET) studies with 2-[(18)F]-fluoro-2-deoxy-D-glucose (FDG) and (11)C-labelled Pittsburgh Compound B (PIB) are used to assess metabolism and cerebral amyloid-β deposition, respectively. Regional cerebral metabolism and blood flow (...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336325/ https://www.ncbi.nlm.nih.gov/pubmed/30653612 http://dx.doi.org/10.1371/journal.pone.0211000 |
Sumario: | In Alzheimer’s Disease (AD) dual-tracer positron emission tomography (PET) studies with 2-[(18)F]-fluoro-2-deoxy-D-glucose (FDG) and (11)C-labelled Pittsburgh Compound B (PIB) are used to assess metabolism and cerebral amyloid-β deposition, respectively. Regional cerebral metabolism and blood flow (rCBF) are closely coupled, both providing an index for neuronal function. The present study compared PIB-derived rCBF, estimated by the ratio of tracer influx in target regions relative to reference region (R(1)) and early-stage PIB uptake (ePIB), to FDG scans. Fifteen PIB positive (+) patients and fifteen PIB negative (-) subjects underwent both FDG and PIB PET scans to assess the use of R(1) and ePIB as a surrogate for FDG. First, subjects were classified based on visual inspection of the PIB PET images. Then, discriminative performance (PIB+ versus PIB-) of rCBF methods were compared to normalized regional FDG uptake. Strong positive correlations were found between analyses, suggesting that PIB-derived rCBF provides information that is closely related to what can be seen on FDG scans. Yet group related differences between method’s distributions were seen as well. Also, a better correlation with FDG was found for R(1) than for ePIB. Further studies are needed to validate the use of R(1) as an alternative for FDG studies in clinical applications. |
---|